Neurotoxicity induced by antineoplastic proteasome inhibitors

NeuroToxicology

Volumn 43, Issue , 2014, Pages 28-35

  Alé, Albert ^a   Bruna, Jordi ^a   Navarro, Xavier ^a   Udina, Esther ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Bortezomib; Carfilzomib; Neurotoxicity; Peripheral neurophathy; Proteasome inhibitors

Indexed keywords

26S PROTEASOME; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; DELANZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IPSI 001; IXAZOMIB; LACTACYSTEINE; LEVACECARNINE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P53; SALINOSPORAMIDE A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UBIQUITIN; UNCLASSIFIED DRUG; CYTOSTATIC AGENT;

AGGRESOME; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CHEMOTHERAPY; CYTOSKELETON; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; EXPERIMENTAL MODEL; GENETIC RISK; HUMAN; HYPERALGESIA; IN VIVO STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NERVE CELL CULTURE; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN AGGREGATION; SPINAL GANGLION; TOXICITY TESTING; TREATMENT OUTCOME; ALLODYNIA; APOPTOSIS; AUTONOMIC DYSFUNCTION; AXONAL INJURY; CANCER INCIDENCE; COLD SENSITIVITY; CONSTIPATION; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEAT SENSITIVITY; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MYELOMA CELL; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SENSORY NERVE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMICALLY INDUCED; NEUROTOXICITY SYNDROMES;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES; PROTEASOME INHIBITORS;

EID: 84905901946     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2014.02.001     Document Type: Article

References (91)

1. Alé A., Bruna J., Morell M., van de Velde H., Monbaliu J., Navarro X., et al. Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model. Exp Neurol 2014, [in press].
2. Arastu-Kapur S., Anderl J.L., Kraus M., Parlati F., Shenk K.D., Lee S.J., et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011, 17(9):2734-2743.
3. Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012, 82(1):51-77.
4. Azoulay D., Lavie D., Horowitz N., Ben-Yehuda D. Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma. Br J Haematol 2010, 164:454-456.
5. Badros A., Goloubeva O., Dalal J.S., Can I., Thompson J., Rapoport A.P., et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007, 110(5):1042-1049.
6. Baiz D., Pozzato G., Dapas B., Farra R., Scaggiante B., Grassi M., et al. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 2009, 91(3):373-382.
7. Bennett B.K., Park S.B., Lin C.S-Y., Friedlander M.L., Kiernan M.C., Goldstein D. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 2012, 20(11):2959-2967.
8. Bringhen S., Larocca A., Rossi D., Cavalli M., Genuardi M., Ria R., et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010, 116(23):4745-4753.
9. Broyl A., Corthals S.L., Jongen J.L., van der Holt B., Kuiper R., de Knegt Y., et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010, 11(11):1057-1065.
10. Bruna J., Alé A., Velasco R., Jaramillo J., Navarro X., Udina E. Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. J Peripher Nerv Syst 2011, 16(3):199-212.
11. Bruna J., Udina E., Alé A., Vilches J.J., Vynckier A., Monbaliu J., et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 2010, 223(2):599-608.
12. Cao Z., Gao Y., Bryson J.B., Hou J., Chaudhry N., Siddiq M., et al. The cytokine interleukin-6 is sufficient but not necessary to mimic the peripheral conditioning lesion effect on axonal growth. J Neurosci 2006, 26(20):5565-5573.
13. Carozzi V.A., Canta A., Oggioni N., Sala B., Chiorazzi A., Meregalli C., et al. Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 2010, 226(2):301-309.
14. Carozzi V.A., Renn C.L., Bardini M., Fazio G., Chiorazzi A., Meregalli C., et al. Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse. PLOS ONE 2013, 8(9):e72995.
15. Casafont I., Berciano M.T., Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res 2010, 17(2):167-178.
16. Cata J.P., Weng H-R., Burton A.W., Villareal H., Giralt S., Dougherty P.M. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007, 8(4):296-306.
17. Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C., et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007, 204(1):317-325.
18. Cavaletti G., Jakubowiak A.J. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010, 51(7):1178-1187.
19. Chari A., Mazumder A.J.S. Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics 2010, 28(4):273-287.
20. Choy M.S., Chen M.J., Manikandan J., Peng Z.F., Jenner A.M., Melendez A.J., et al. Up-regulation of endoplasmic reticulum stress-related genes during the early phase of treatment of cultured cortical neurons by the proteasomal inhibitor lactacystin. J Cell Physiol 2011, 226(2):494-510.
21. Corso A., Mangiacavalli S., Varettoni M., Pascutto C., Zappasodi P., Lazzarino M. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 2010, 34(4):471-474.
22. Corthals S.L., Kuiper R., Johnson D.C., Sonneveld P., Hajek R., van der Holt B., et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011, 96(11):1728-1732.
23. Crawford L.J., Walker B., Irvine A.E. Proteasome inhibitors in cancer therapy. J Cell Commun Signal 2011, 5(2):101-110.
24. Csizmadia V., Csizmadia E., Silverman L., Simpson C., Raczynski A., O'Brien L., et al. Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro. Vet Pathol 2010, 47(2):358-367.
25. Csizmadia V., Raczynski A., Csizmadia E., Fedyk E.R., Rottman J., Alden C.L. Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro. Neurotoxicology 2008, 29(2):232-243.
26. Favis R., Sun Y., van de Velde H., Broderick E., Levey L., Meyers M., et al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 2011, 21(3):121-129.
27. Freimann H., Calderoni A., Cornu P., Olie R. Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Swiss Med Wkly 2007, 137:317-322.
28. Gallerani E., Zucchetti M., Brunelli D., Marangon E., Noberasco C., Hess D., et al. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2013, 49(2):290-296.
29. Gartel A.L. A new target for proteasome inhibitors: FOXM1. Expert Opin Investig Drugs 2012, 19(2):235-242.
30. Gill J.S., Windebank a J. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 1998, 101(12):2842-2850.
31. Goldberg A.L. Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol 2012, 199(4):583-588.
32. Grisold W., Cavaletti G., Windebank A.J. Peripheral neuropathies from chemotherapeutics and targeted agents. Neuro-Oncology 2012, 14:45-54.
33. Hershman D.L., Weimer L.H., Wang A., Kranwinkel G., Brafman L., Fuentes D., et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011, 125(3):767-774.
34. Hideshima T., Chauhan D., Schlossman R., Richardson P., Anderson K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001, 20(33):4519-4527.
35. Hideshima T., Ikeda H., Chauhan D., Okawa Y., Raje N., Podar K., et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114(5):1046-1052.
36. Hideshima T., Mitsiades C., Akiyama M., Hayashi T., Chauhan D., Richardson P., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003, 101(4):1530-1534.
37. Huang Q., Figueiredo-Pereira M.E. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis 2010, 15(11):1292-1311.
38. Jagannath S., Barlogie B., Berenson J., Siegel D., Irwin D., Richardson P.G., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127(2):165-172.
39. Jagannath S., Barlogie B., Berenson J.R., Siegel D.S., Irwin D., Richardson P.G., et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008, 143(4):537-540.
40. Jagannath S., Durie B.G.M., Wolf J., Camacho E., Irwin D., Lutzky J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005, 129(6):776-783.
41. Janelsins M.C., Mastrangelo M.A., Park K.M., Sudol K.L., Narrow W.C., et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 2008, 173(6):1768-1782.
42. Janes K., Doyle T., Bryant L., Esposito E., Cuzzocrea S., Ryerse J., et al. Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. Pain 2013, 154(11):2432-2440.
43. Jeter A., Kang Y. Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy. Exp Hematol Oncol 2012, 1(1):20.
44. Klimaschewski L., Hausott B., Ingorokva S., Pfaller K. Constitutively expressed catalytic proteasomal subunits are up-regulated during neuronal differentiation and required for axon initiation, elongation and maintenance. J Neurochem 2006, 96(6):1708-1717.
45. Kopito R.R. Aggresome, inclusion bodies and protein aggregation. Trends Cell Biol 2000, 10:524-530.
46. Kortuem K.M., Stewart A.K. Carfilzomib. Blood 2013, 121(6):893-897.
47. Kuhn D.J., Hunsucker S.A., Chen Q., Voorhees P.M., Orlowski M., Orlowski R.Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 2009, 113(19):4667-4676.
48. Landowski T.H., Megli C.J., Nullmeyer K.D., Lynch R.M., Dorr R.T. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005, 65(9):3828-3836.
49. Laser H., Mack T.G.A., Wagner D., Coleman M.P. Outgrowth and causes dying-back degeneration in primary culture. J Neurosci Res 2003, 74(6):906-916.
50. Lee D.H., Goldberg a L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998, 8(10):397-403.
51. Lema M.J., Foley K.M., Hausheer F.H. Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain. Oncologist 2010, 15(Suppl. 2):3-8.
52. Li C., Chen S., Yue P., Deng X., Lonial S., Khuri F.R., et al. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 2010, 285(21):16096-16104.
53. Mazumder A., Jagannath S. Thalidomide and lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 2006, 19(4):769-780.
54. Meregalli C., Canta A., Carozzi V.A., Chiorazzi A., Oggioni N., Gilardini A., et al. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain 2010, 14(4):343-350.
55. Mols F., Beijers T., Lemmens V., van den Hurk C.J., Vreugdenhil G., van de P-F.L. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013, 31(21):2699-2707.
56. Moreau P., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., Grishunina M., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12(5):431-440.
57. Moreau P., Richardson P.G., Cavo M., Orlowski R.Z., San Miguel J.F., Palumbo A., et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012, 120(5):947-959.
58. Myers R.R., Campana W.M., Shubayev V.I. The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today 2006, 11(1-2):8-20.
59. Noda C., Tanahashi N., Shimbara N., Hendil K.B., Tanaka K. Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats. Biochem Biophys Res Commun 2000, 277(2):348-354.
60. Orlowski R.Z., Eswara J.R., Lafond-walker A., Dang C.V., Grever M.R., Orlowski M. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor tumor growth inhibition induced in a murine model of human Burkitt' s lymphoma by a proteasome inhibitor. Leukemia 1998, 48:4342-4348.
61. Palanca A., Casafont I., Berciano M.T., Lafarga M. Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons. Cell Mol Life Sci 2013, [in press].
62. Parlati F., Lee S.J., Aujay M., Suzuki E., Levitsky K., Lorens J.B., et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009, 114(16):3439-3447.
63. Pike C.T., Birnbaum H.G., Muehlenbein C.E., Pohl G.M., Natale R.B. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012, 2012:913848.
64. Poruchynsky M.S., Sackett D.L., Robey R.W., Ward Y., Annunziata C., Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells. Cell Cycle 2008, 7:940-949.
65. Prommer E.E. Topical analgesic combinations for bortezomib neuropathy. J Pain Symptom Manage 2009, 37(3):3-5. [U.S. Cancer Pain Relief Committee].
66. Qiu J.H., Asai a, Chi S., Saito N., Hamada H., Kirino T. Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J Neurosci 2000, 20(1):259-265.
67. Ravaglia S., Corso A., Piccolo G., Lozza A., Alfonsi E., Mangiacavalli S., et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008, 119(11):2507-2512.
68. Redic K. Carfilzomib: a novel agent for multiple myeloma. J Pharm Pharmacol 2013, 65(8):1095-1106.
69. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24(19):3113-3120.
70. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352(24):2487-2498.
71. Richardson P.G., Sonneveld P., Schuster M.W., Stadtmauer E.A., Facon T., Harousseau J.-L., et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009, 144(6):895-903.
72. Rockwell P., Yuan H., Magnusson R., Figueiredo-Pereira M.E. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys 2000, 374(2):325-333.
73. Ruschak A.M., Slassi M., Kay L.E., Schimmer A.D. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011, 103(13):1007-1017.
74. Russell J., Windebank A., Mcniven M., Brat D., Brimijoin W. Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity. Brain Res 1995, 676(2):258-267.
75. Saifee T.A., Elliott K.J., Rabin N., Yong K.L., D'Sa S., Brandner S., et al. Bortezomib-induced inflammatory neuropathy. J Peripher Nerv Syst 2010, 15(4):366-368.
76. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359(9):906-917.
77. Schubert U., Antón L.C., Gibbs J., Norbury C.C., Yewdell J.W., Bennink J.R. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000, 404(6779):770-774.
78. Siegel D., Martin T., Nooka A., Harvey R.D., Vij R., Niesvizky R., et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies. Haematologica 2013, 98(11):1753-1761.
79. Staff N.P., Podratz J.L., Grassner L., Bader M., Paz J., Knight A.M., et al. Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. Neurotoxicology 2013, 39C:124-131.
80. Sullivan P.G., Dragicevic N.B., Deng J-H., Bai Y., Dimayuga E., Ding Q., et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem 2004, 279(20):20699-20707.
81. Lauren E., Espeset L., Podratz J., Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006, 27(6):992-1002.
82. Tanner K.D., Levine J.D., Topp K.S. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 1998, 395(4):481-492.
83. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science 2002, 296(5575):1991-1995.
84. Topp K.S., Tanner K.D., Levine J.D. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 2000, 424(4):563-576.
85. Trevisan G., Materazzi S., Fusi C. Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy by TRPA1 blockade. Cancer Res 2013, 73:3120-3131.
86. Velasco R., Petit J., Clapés V., Verdú E., Navarro X., Bruna J. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst 2010, 15(1):17-25.
87. Wang C. NF-kB antiapoptosis induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress Caspase-8 activation. Science 1998, 281(5383):1680-1683.
88. Watanabe T., Nagase K., Chosa M., Tobinai K. Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. Br J Cancer 2010, 103(10):1580-1587.
89. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008, 13(1):27-46.
90. Xiao W.H., Zheng H., Zheng F.Y., Nuydens R., Meert T.F., Bennett G.J. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience 2011, 199:461-469.
91. Zheng H., Xiao W.H., Bennett G.J. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol 2012, 238(2):225-234.